n/a
Article Publish Status: FREE
Abstract Title:

Therapeutic effects of lentinan on inflammatory bowel disease and colitis-associated cancer.

Abstract Source:

J Cell Mol Med. 2019 02 ;23(2):750-760. Epub 2018 Nov 24. PMID: 30472806

Abstract Author(s):

Yanrong Liu, Jianmin Zhao, Yali Zhao, Shumin Zong, Yixuan Tian, Shuang Chen, Meng Li, Huijuan Liu, Qiang Zhang, Xueshuang Jing, Bo Sun, Hongzhi Wang, Tao Sun, Cheng Yang

Article Affiliation:

Yanrong Liu

Abstract:

In this study, we investigated the therapeutic potential of lentinan in mouse models of inflammatory bowel disease (IBD) and colitis-associated cancer (CAC). Lentinan decreased the disease activity index and macroscopic and microscopic colon tissue damage in dextran sulphate sodium (DSS)-induced or TNBS-induced models of colitis. High-dose lentinan was more effective than salicylazosulfapyridine in the mouse models of colitis. Lentinan decreased the number of tumours, inflammatory cell infiltration, atypical hyperplasia and nuclear atypia in azoxymethane/DSS-induced CAC model. It also decreased the expression of pro-inflammatory cytokines, such as IL-13 and CD30L, in IBD and CAC model mice possibly by inhibiting Toll-like receptor 4 (TLR4)/NF-κB signalling and the expression of colon cancer markers, such as carcinoembryonic antigen, cytokeratin 8, CK18 and p53, in CAC model mice. In addition, lentinan restored the intestinal bacterial microbiotal community structure in IBD model mice. Thus, it shows therapeutic potential in IBD and CACmodel mice possibly by inhibiting TLR4/NF-κB signalling-mediated inflammatory responses and disruption of the intestinal microbiotal structure.

Print Options


This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.